View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 5, 2022updated 11 Jul 2022 2:13pm

Gritstone reports positive data from initial arm of Covid-19 vaccine trial

In the trial, the vaccine was well-tolerated with favourable safety profile.

By Vishnu Priyan

Gritstone bio has reported positive results from the first cohort of Phase I CORAL-BOOST clinical trial of its CORAL self-amplifying mRNA (samRNA) vaccine for Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Findings showed that the 10µg vaccine dose offered robust neutralising antibody responses to Spike and strong CD8+ T cell responses.

One of four trials of the CORAL programme, CORAL-BOOST is assessing the reactogenicity, safety and immunogenicity of the vaccine directed against Spike and highly conserved non-Spike T cell epitopes (TCE) as a Covid-19 booster shot.

This ongoing trial in the UK enrolled healthy adult subjects aged 60 years or above and were vaccinated with two doses of AstraZeneca’s AZD1222 (Vaxzevria) Covid-19 vaccine.

New CD8+ T cell responses across a wide range of non-spike epitopes, including several established T cell targets, were observed in the trial, which indicates the vaccine’s variant-proof immunity potential.

The vaccine was also found to be well-tolerated in the trial.

It also showed an encouraging safety profile without any grade 3/4 side effects or unexpected reactogenicity or safety issues noted in ten healthy trial adult subjects.

Gritstone bio co-founder, president and CEO Andrew Allen said: “We designed our Covid-19 vaccines to drive broad CD8+ T cell immunity, an additional key layer of protection against viruses.

“This innovation enables the inclusion of a wide array of highly conserved viral epitopes, potentially creating an immune state that may offer more robust clinical protection against current and future SARS-CoV-2 variants and be a first step toward developing a pan-coronavirus vaccine.”

Presently, the trial dose-escalated to a 30mg dose of the vaccine.

With the latest development, the company is modifying the trial to raise the subject enrolment to 120 and assess the inclusion of a second samRNA-Spike-TCE dose of the shot.

Last September, Gritstone dosed the first subjects in a Phase I trial of a self-amplifying mRNA Covid-19 vaccine.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena